Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medication Talk - Expert Insights on Drug Therapy & Patient Care

Medication Talk - Expert Insights on Drug Therapy & Patient Care artwork

Managing Agitation in Dementia

Jul 1, 202228 minAudio

TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Dr. Russ Blackwelder, MD, MDiv, CMD, Associate Professor and Director of Geriatric Education from the MUSC Department of Family Medicine and Co-Medical Director from The Village at Summerville about managing agitation in patients with dementia. Listen in as they discuss practical strategies for managing agitation in patients with dementia...and clarify pros and cons of various medications. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board: Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor Health Anthony A. Donato, Jr., MD, MHPE, Associate Program Director, Internal Medicine from the Reading Health System, and Professor of Medicine at the Sidney Kimmel Medical College at Thomas Jefferson University Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor, Department of Pharmacy Practice at the Oregon Health and Science University None of the speakers have anything to disclose. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. 🗪 Send us Fan Mail Email us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Medication Talk is a production of TRC Healthcare. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here. Learn more about our product offerings at trchealthcare.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

NarratorWelcome to Medication Talk, the official podcast of TRC Healthcare, Homo pharmacist letter, prescribers letter, RX Advanced, and the most trusted clinical resources. On today's episode, we'll be listening in as our expert panel discusses practical strategies for managing agitation in patients with dementia and clarifies pros and cons of various medications. Our guest today is Dr. Russ Blackwelder from the MUSD Department of Family Medicine and the Village at Somerville. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board, Dr.

NarratorAndrea Darby Stewart from Honor Health, Dr. Anthony Donato from the Reading Health System, and Dr. Craig Williams from the Oregon Health and Science University. This podcast is an extract from TRC's Emerging Recommendations panel webinar. Each month, experts and frontline providers discuss current medication therapy topics and practical recommendations to include in TRC's letter articles. The full webinar originally aired on May 18, 2022.

CE NarratorAnd now the CE information.

NarratorPlease log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. None of the speakers have anything to disclose. Now, let's join TRC editor, Dr. Lori Dickerson, and start our discussion.

Lori DickersonAgitation affects up to seven in ten patients with dementia. So we want to discuss this article to bring up approaches to management of these challenging cases. And so, Russ, to get us started, can you briefly comment on the behavioral disturbances in patients with dementia and if agitation is the most common presentation of these behaviors?

Russ BlackwelderSo this is a major issue, and the greatest risk factor for dementia is age. So as our population gets older, inevitably we're going to be seeing more and more dementia. And reflecting over the past couple of years, just the toll that agitation takes in our caregivers, as we've all dealt with COVID, the impact of that, not only families, but also staff and nursing homes and so forth. So agitation, some estimates I've seen, they've even put it up to nine in 10 patients.

Russ BlackwelderSafe to assume pretty much if somebody has dementia, at some point they're going to have agitation. Well, and even more importantly, the one that part of this that we really worry about too is the when agitation becomes aggressive and violent. And those rates seem to be around 15 to 20% of people with dementia.

Lori DickersonVery good. I was hoping we get to sort of that consequence bit. And you know, we do talk uh in the next part of our article, Russ, about non-drug measures and how they're critical and helping manage uh behavioral problems, such as agitation, of course, and others. Um, so how do you help families and caregivers sort of set up these non-drug measures and the environment that is most conducive to sort of minimizing agitation?

Russ BlackwelderThis is a challenging topic to talk about because it's much easier to talk about the things that we shouldn't do when talking about dementia-related agitation. Um, we know that once we get to the medication options, none of those are great choices. So if we can really hone in on the non-drug measures, um, eliminate and prevent problems before they rear their heads, uh, we know for sure providing support for caregivers and staff and education on how to handle dementia patients is also key.

Russ BlackwelderSo if the uh demented patient says the sky is red, then you just go with it and say the sky is red and agree. Uh don't give too many choices to the person. And as the slides say, those structured activities and try to keep night, night, day, day. Um, all those types of things are very important.

Lori DickersonAnd Andrea, just to call on you too, and and sort of, you know, setting up expectations for families and caregivers and managing uh these patients, what sort of advice do you typically provide?

Andrea Darby StewartYeah, you know, I really try and emphasize that concept of daily routine. Um, uh disruption of routine, particularly when your loved one is doing well and you think, oh, maybe we can try something new or different, um, often will increase that level of agitation. Um, and some one of the other things that I always try and emphasize is make sure that your loved one has their hearing assistive devices or uh visual assistive devices, their glasses available to them. When we start to remove, you know, a sensory perception or make it more difficult, um, that can often lead to increases in agitation as well.

Lori DickersonExcellent point. Very good point, Andrea. Thank you for that. And I do think that people think, oh, things are going well. Let's take you know, mom out to lunch or something, and then everything sort of, you know, um sort of trickles down from there. So that's a great point to bring up. Thank you for that. And, you know, Andy, next we bring up the importance of looking for other causes uh that might be triggering um this agitation. And so in your hospitalized patients, you know, are the examples that we list in our article here the most common causes that you would see as as triggers, or what sort of things do you typically see?

Anthony A. DonatoYou've got a pretty good list, and and absolutely it's the new drugs, it's the new infections, uh, pain, poop, um, I'm in a new place. Uh, I think Andrew just said uh I can't hear, so I misperceive stuff, I can't see stuff. Um uh the uh delirium has a long, long list. And uh um I think you this is probably something could be uh 20 pages, but I think your start is good enough here.

Lori DickersonOkay, very good.

Russ BlackwelderThis is the easiest question to ask medical students and residents is what causes agitation? Because there really is no wrong answer.

Lori DickersonThat's right. The list is long, right? Um now, you know, Russ, we do next in the article bring up the idea of trying acetamenophen. Um and, you know, we have had several folks uh who work with this population, especially in uh skilled nursing facilities, suggest this as an option. Scheduled acetamenophen up to three grams a day is worth a try as a way to um perhaps address pain uh that's undiagnosed or unstated. So I'm curious about your thoughts on this approach and um if you find it effective.

Russ BlackwelderYeah, this falls into the realm of our oath of doing no harm. And there are some studies that suggest that acetominophen can have some benefit in these patients. The theory is that they're not able to communicate with us and really articulate what's bothering them. They might not even be aware of what's bothering them, and the um the schedule to acetaminophen takes the edge off just enough to calm things down. Um, in my own practice, I use this a decent amount because I know that other options uh which we'll talk about aren't that great and all come with significant side effects.

Russ BlackwelderUm, this particularly, you know, we use it a good bit for um in the hospital prophylactically too, when we know people are gonna have pain and try to get ahead of it and prevent problems down the road.

Lori DickersonAnd I'm curious, uh Andrea, is this something that you have also tried with in this population?

Andrea Darby StewartYeah, absolutely. Although I think like just about everyone else that I offer acetamidifine to, um I get the oh, that's not gonna work even from caregivers. But uh oftentimes they're willing to give it a try. And uh, we can see some benefit both in the hospital as well as the ambulatory setting.

Lori DickersonOkay. Well, I think uh as you said, Russ, um, it's easier to talk about the things that you don't want to do for for agitation in these patients than the things that I are that you do want to do. And so I think we've talked about sort of the screening and sort of the the lifestyle and and socialization and ways to sort of manage the situation. So let's now talk about medications. And I guess my first question is you know, when you are at the point where you're ready to discuss medications with families and caregivers, how do you kind of present um the pros and cons or risks and benefits with uh these medications?

Russ BlackwelderYeah, I I, you know, commonly staff and family as well want to go pretty heavy right on and try to um significantly sedate the person that that's the goal they're after, which is um not what we're after. And I'm quick to bring experts in the room with me. And what I mean by that is I I print out the American Geriatric Society Choosing Wisely guidelines and and um and show them that with uh I think number four on the list is don't use benzodiazepines and agitated people.

Russ BlackwelderNumber two on their list is don't use antipsychotics as first choice. Um and then go through some of these other potentially safer options that that certainly have side effects, and we go through those, but um that we can try first. And and typically Tylenol is the oracinaminophen is the the first thing that I go to, and then once we're past that, then we're really talking about okay, here are our options, let's see what can work. And um, with the acknowledgement too, that uh in these situations, the patient that we're talking about isn't really our patient, just our patient, the family or the staff is also in the situation our patient that we're dealing with as well.

Lori DickersonAnd Russ, you know, generally if we looked at these medications sort of globally, they're would you agree that they're quote only modestly effective? Completely in terms of yeah, yeah. So I think that's a big issue too, right? People are looking for that magic bullet and they're really not that effective.

Craig WilliamsSo we don't talk on that, Lori. Yes, are they even are they even modestly I'm more familiar with these for the anxiety indications? And yeah, you know, Andy Price, I you know, we would never reach for these, certainly on the inpatient side, and hope they would help in you know a day or two. But are there actually studies that they reduce agitation long-term dementia patients that maybe I'm just not familiar with?

Lori DickersonThat's a good point. And actually, Craig, I've been wondering if the word modestly is too strong here and if it should be, you know, you know, maybe uh we should back off on that. Um what do you think about that, Russ?

Russ BlackwelderI I agree, and and I think in some ways these things give people false hope. Um my sense, and this is a hard thing to study and prove, but a lot of times what we do is uh it just buys time for whatever's bothering the person to kind of settle down and everybody uh gets to a new status quo and everything's better.

Anthony A. DonatoLaurie, this is Andy. Uh if I could just add though, uh there are definitely small indications for this. My patients that are hallucinating with their agitation, and my patients that I think Ross said it very well. If the if the wife is so burned out that these hallucinations are going to make him get placed, then you gotta weigh the pros and cons of can I get this guy calm enough that that being with the wife is more important than anything else, and can I pull it off?

Lori DickersonGreat point. And um, if we go back to that wording with modestly, I think we might look at words like uh aren't overly effective or aren't that effective, maybe instead of modestly. And so just curious, uh Craig, if you know what you think about maybe a flip in that wording.

Craig WilliamsYeah, no, I think that'd be good. And the thing I have to add is as I think to Russ's point, you know, knowing what medicines to avoid is just as important as the things I'm I wonder if that limit other meds or a little more discussion that should not somewhere move above what to try for, you know. Knowing what not to use to me is just as important as maybe trying the things we're suggesting in that case.

Lori DickersonGood point, good point. Um, and we will look at uh doing that little flip to the article. Good point. Well, let's talk about the meds that are used. And um, we do make the recommendation to start you know, if you're going to try medication, to try an SSRI first. And actually, we say here on our slide, we say try an SSRI or SNRI first, but we've since sort of edited that and really focused on trying an SSRI first, because I think the SSRIs have really the majority of the data in this population, which isn't a huge amount of data, um, but more so than SNRIs.

Lori DickersonAnd so uh Russ, what are your thoughts here on starting with an SSRI if you're going to use something?

Russ BlackwelderI would definitely agree with SSRI before SNRI. Um the the two SSRIs that have the most uh data behind them uh for this are Zoloft and Cetaliprim. Um for some, you know, be aware that the cetoprim does have a higher risk of prolonged QT than the searchrolling does. And then also a key key takeaway to keep in mind is that the doses are much lower in older adults because we worry about those side effects such as SIADH falls, hip fractures, and those types of things.

Russ BlackwelderUm it's interesting, it'll be interesting to see if there's more data that comes out on this um, or actually there'll be less data, probably SNRIs, because um SNRIs were added to the BIERS criteria, um, kind of upgraded on being careful with those in elderly people in the 2019 iteration of the BIERS criteria. So previously we thought maybe those were a little bit safer, and now no, that's not the case.

Lori DickersonUh good point, and maybe another reinforcement to why we would pull that out or consider an SNRI for patients with possible neuropathy. Of course, we know to manage other comorbidities and but not specifically using an SNRI for the agitation uh without necessarily the underlying condition. So I think that's helpful. And um I also like uh your point about SIDH, which of course is a big issue in these folks. Um, so if we are going to try an SSRI, Russ, we state uh again, you have the dosing that we've talked about.

Lori DickersonIf an SSRI doesn't help in eight to 12 weeks to taper it off. And curious about your thoughts on this statement, if that's practical, and you knowing that sometimes it takes that long for these meds to work when we're thinking about sort of traditional depression. What are your thoughts on that?

Russ BlackwelderYeah, I would I I think I would agree with that. You know, it depends kind of on on what doses you achieve to get to the eight to 12 week mark. I I think and I typically and uh what I do is I do wean it off and go in slow. And if I don't notice any side effects, maybe I'll go a little bit more aggressively. Um, all that to say, and I I feel like I I should have said this earlier at the beginning of this discussion, since we're talking about meds and tapering, is also to be really, really mindful of what else is on this med list of what the person's getting.

Russ BlackwelderUm because in geriastrics we fix more problems by taking stuff away than we do at them, right?

Lori DickersonYeah.

Russ BlackwelderSo it benefits from our tapering conversation. I'd be interested in other people's thoughts on the um tapering if somebody's just on it for eight to twelve weeks.

Lori DickersonAndrea, what are your thoughts here?

Andrea Darby StewartIs this sort of your general practice? Um, you know, I think it's a I think it would be a very reasonable option because the other challenge is that uh we may not get accurate information from the patient about what they're experiencing as we abruptly stop a medication. Um so tapering may at least allow us to um you know mitigate some of those um adverse effects. And I'm just curious about the use of trazodone in the evening to help with sleep because that may provide some benefit with anxiety and depression, um, a little bit more sedating, um which has its pluses and its minuses.

Lori DickersonSo yeah, so can you uh comment on trazodone also, Russ? What where do you sort of plug that in as an option?

Russ BlackwelderIt's an option, it's in the toolbox. Um, I would typically, especially if sleep is what I'm after, and I think if we can get the sleep cycle uh more in line, we'll see some improvement. I typically go with a melatonin agonist first, even just low doses of melatonin. Some of what I've seen uh or the concern with trazodonin, and maybe this is okay because we're gonna be working on weaning it down anyway over time, is it that it can become tachyphylactic?

Lori DickersonOr it is tachyphylactic a little bit of sleep. Okay. Good point. And Andy, did you have something you wanted to add?

Anthony A. DonatoYeah, there's something about the entire article that bothers me a little bit. I was hoping you could just help me with this. Um, could we make this managing chronic persistent agitation and dementia? Because I I think uh you could read this article and say, oh, someone's having a bad night, let me pick a drug. And everything in here, I think your intention is this is something where someone's having a behavior problem every night, most nights, and I've got to adjust things. And I I that's not entirely clear from this, if you could help me with that.

Lori DickersonThat's a great point, Andy. And I think that is uh clearly that was our intention. And um and in in our editing, it might have gotten whittled out of here. So we'll we'll work on making that clear that this is a persistent problem, not an intermittent problem. We do actually want have uh a point about intermittent problems, but I first I want to talk about the antipsychotics. And, you know, I think traditionally, right, antipsychotics have certainly been what's been used a lot of times in agitation, and um, and then the box warning came out, and certainly not very great efficacy data.

Lori DickersonAnd so, you know, we make the point to save antipsychotics for severe or dangerous symptoms. Um, and so Russ, is that sort of where you leave these for for dangerous symptoms when someone's at risk of harming themselves or others?

Russ BlackwelderIt is, is when there's an imminent threat, and and that's when we we go to them. And if if other those uh other non-pharmacologic measures have failed and um really need something, then then we'll go to these and um are we never happy about having to do it either. Um always start the lowest possible dose is you can always add more.

Lori DickersonMm-hmm. Mm-hmm. And you know, we've had a lot of comments and questions coming in, and actually from our peer reviewers before tonight, too, about the uh box warning. And if we should actually even say that they have a box warning, I think a lot of our comments coming in is it really practical to have that as a priority, is a reason not to use these meds when you're talking about a you know, a situation that's a very difficult situation. We felt it was important to put the box warning in there because, well, there is a box warning, um, and it is about death in older patients with dementia.

Lori DickersonSo uh Andrea, actually I'm curious from you too, like about this box warning. Is this something that you are thinking about and um is sort of making you more hesitant to try these meds and think think that we should uh consider keeping it in the article?

Andrea Darby StewartThat's a great question. Um, I don't think that it's um inappropriate to have a conversation with the family. And again, we get back to shared decision making. If the patient is so distressed or it's causing such distress to the family for the agitation symptoms that they're having. And a patient who is older with dementia, we are here to palliate symptoms. Um and so I think my practice is to say you may see this because when they go to fill it, they're going to, if they read anything, there's a big box on the written information that says this could cause death or stroke.

Andrea Darby StewartUm, so I would rather them hear that from me and have us have a discussion about why we would choose to use this medication to assist the patient in achieving what we hope their goal would be of being more comfortable.

Craig WilliamsI think those are great comments. Yeah, this is a tough uh it's certainly a tough subject when patients get to this point in their dementia. But yeah, I would agree that you know black box warning for death deserves to be mentioned in the article. And Angie's right, you you want someone else to discuss that with the patient before they get handed something by the pharmacist and read it on there.

Lori DickersonYou know, go ahead, someone was gonna speak up.

Russ BlackwelderYeah, I was going to Lori, this this raises um an interesting ethical um discussion. When I ask residents and colleagues and I give them the option of, hey, let's imagine way into the way, way, way into the future, you're so demented and agitated that you're a threat either to yourself or somebody else. Would you want would you want them to give you anything psychotic? I've never had somebody say no. Um I wonder if maybe this is something that even goes into uh some of our healthcare power attorneys and things like that. Uh, right, right. Discussion with people.

Russ BlackwelderYeah.

Lori DickersonClearly shared decision making and and making it clear that we're, you know, having that discussion with uh the family and caregivers as a as a big part of that. Well, you know, we have another question about the antipsychotics. We do talk about which agents to use, and I think you know, there's data with differing agents, but we do have a question about the the dosing, Russ. And we say to give one third, one half the usual starting dose and titrate slowly and taper off if there's no benefit in about four weeks. And um, we were sort of noodling on the wording about titrate slowly because what do you titrate to?

Lori DickersonWhen do you stop titrating? How far do you go? Um, and how far how much are you titrating in those four-week time in that four-week time period? And so I'm curious, sort of like on how you uh address this, and are you really just sort of getting to where you want to be at four weeks uh for that stopping?

Russ BlackwelderYeah, it uh to speak anecdotally, uh, I think we've already had our answer of what's going to work before the four weeks. And um, and certainly we titrate until we we find an effective dose for what we're hoping will will calm things down. And again, my suspicion is oftentimes uh things settle down. Um maybe because of or in addition to the medication effect, but then maybe the situation changes, the environment changes, something else happens that we then we see a benefit, and we can get to a little bit of a steady state and then leave it there for a while until everything calms down and then start to start backing off.

Russ BlackwelderYep, and weaning through shared decision making as well.

Lori DickersonAnd so that's the next uh point in the article is if patients do respond, try tapering within four months because many could start. Without relapsing since symptoms wax away. And I think that's uh just exactly what you were just saying. So um, so the wording about titrating slowly and you know getting to the minimally effective dose, there's not really a hard and fast rule to that. It's really going to be um patient-specific and and daily specific, it sounds like.

Anthony A. DonatoAgree. Yeah, absolutely.

Lori DickersonVery good. And then um we do uh want to talk about benzos because this always comes up. And uh, you know, of course, lots of times uh uh this will be suggested maybe by a family member or caregiver. And Andy, we recommend against using benzodazipines other than for situational PRN use, such as, for example, in the nursing home, around bathing or foot care or some other sort of uh disruptive event. And I'm just curious in the hospital setting, is this sort of your approach? Um, and then we'll talk about more of the nursing home setting.

Anthony A. DonatoYeah, my my approach is is almost never the the only yes for me is if they're coming off a chronic sedative like alcohol or they were on Xanax. Uh but I mean, I I I would say even what you're writing here, I don't like because someone needs to be bathed every day. So I might give it an ad-event every day. Uh, you know, if I transfer somebody to a brand new setting and they need a day or two to reset their sleep, yes, but short of one one-offs, I'm gonna be maybe uh a little more um dictatorial about this and say don't.

Anthony A. DonatoBut I let me defer to Russ on that one.

Lori DickersonYes, because they're probably not bathing every day or getting their in in the in the facility, right, Russ. So that's a good point.

Russ BlackwelderUm I I support you as dictator because I I agree with the the take on that. And um we know this is gonna ultimately disturb people's sleep pattern if they're on it for a while. There's there's significant evidence that it raises the risk of of hip fractures um and and all kinds of issues. Sometimes it can be more activating. Still see it used a lot in in people who are delirious too, which um I'm really hoping we can get get away from that.

Craig WilliamsYes, Adler to you know, and to Andy's point that you know, we remind people when you're reaching for benzo, you may as well reach for uh you know some whiskey or bourbon. It's there's reasons why it works for that withdrawal. And you know, where would you want to give that to a patient? So, yeah, very much.

Lori DickersonYeah, good point. And along those same lines, in in terms of, you know, if you have a situation, Russ, where someone might need a little help getting through, um, we have had questions about why not to use something like an or orally disintegrating tablet, an ODT of um like Zyprexa, for example, allanzepine or Respiridone. And so as opposed to a benzo, I'm curious about your thoughts on that.

Russ BlackwelderYeah, I think that's possible. I I I think it's it's nice to have as an option, and because again, this is this is something where um treatment, the therapies are really gonna have to be tailored to the individual because every situation is so different. Um but I think that's important to keep in mind that those are an option, especially in in hospice situations and and and other things that might come up.

Lori DickersonOkay, very good. And we also uh conclude the piece with um you know some of these uh newer meds, uh new Dexta, new placid, that have been sort of pigeonholed for these situations, but we are recommending against using those. The evidence of benefit is even more limited, I think, than the other agents. And of course, there's safety issues and they cost thousands of dollars a month. And so I'm thinking that you're gonna agree with that statement, Russ.

Russ BlackwelderI do agree, and um, a lot of evidence has come out about nudexta and fall risk. It was really, really, really pushed hard a few years ago in nursing homes with pretty significant consequences.

Lori DickersonOkay.

Craig WilliamsHey Larry wonder real quick goes to uh what Russ has thought is uh back up real quick. We're saying if an antipsychotic is needed, I'd love to see us add there for symptoms. I think a lot of folks still confuse what these drugs are doing, and we have good data they don't treat dementia or delirium, they're just treating agitation symptoms of it. And we're not fixing the dulling process.

Lori DickersonGreat. I'm gonna make that point. That's great. And then it might be for persistent symptoms too, right? Which is to Andy's point. Yeah. Yep. Okay, very good. And one last question to squeeze in. Yeah, this person is saying uh they're used to seeing you know, valproic acid and carbamazepine and some of these older mood stabilizers used. And um curious, Russ, if you're still seeing any of any of that happening in the in the skilled nursing facility.

Russ BlackwelderVery limited. And we might see some people that get get admitted to us that have um maybe been on it from for numerous years and just hadn't been it's very rare. I I think the side effect profile um and really the evidence that has that has come out um there's really not much benefit. And and like I said, the side effects are are pretty significant, especially with valproic acid and platelets and um really causes a lot of problems. So best to avoid it.

NarratorWe hope you enjoyed and gained practical insights from listening into this discussion. Now that you've listened, you can receive CE credit from Pharmacist Letter. Just log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. If you're not yet a Pharmacist Letter subscriber, find out more about our product offerings at TRCHealthcare.com. Be sure to follow or subscribe, rate, and review this show in your favorite podcast app. It helps spread the word about our show and is a great way for you to let us know how we're doing. You can also reach out to provide feedback or make suggestions by emailing us at contact us at trchealthcare.com.

NarratorThanks for listening to Medication Talk.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Navigating Obesity Treatment

    Nov 1, 202634 minAudio

    Listen in as our expert panel walks through today’s full range of obesity treatment options - from older agents like orlistat and phentermine/topiramate to the latest GLP-1 therapies - and how to match the right...

    Credit the people on this episode

  2. Feed Drop: Toxic Yellow Oleander in Weight Loss Products

    Oct 15, 202624 minAudio

    A bonus episode from our sister show, Natural Medicines: Evidence in Practice. Weight loss supplements labeled tejocote, Nuez de la India, or Brazil seeds have been found to contain toxic yellow oleander, and as few as...

    Credit the people on this episode

  3. Managing Poisonings

    Oct 1, 202633 minAudio

    Poisonings are a significant public health concern - in 2024 alone, U.S. poison centers received over 2 million reported exposures. Listen in as our expert panel of toxicologists and poison-center specialists discusses...

    Credit the people on this episode

  4. Decoding the Lipid Guidelines

    Sep 1, 202633 minAudio

    Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk...

    Credit the people on this episode

  5. Estimating Kidney Function in Chronic Kidney Disease

    Aug 1, 202633 minAudio

    Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You’ll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust...

    Credit the people on this episode